Introduction
The Melanoma Research Alliance (MRA) is the world’s largest private nonprofit funder of melanoma research. Based in Washington, D.C., it supports scientific research intended to prevent melanoma, improve diagnosis, develop effective treatments and ultimately end suffering and death caused by the disease.
History and Background
MRA was founded in 2007 by Debra and Leon Black after Debra was diagnosed with Stage II melanoma. The organisation began under the auspices of the Milken Institute with an initial commitment of $25 million.
Since its establishment, MRA has developed an international research portfolio covering laboratory discoveries, translational science, clinical research and patient-focused initiatives.
Mission and Purpose
MRA’s mission is to end suffering and death caused by melanoma by accelerating promising scientific research and collaboration.
Its research priorities include:
- Melanoma prevention and risk prediction
- Early detection and accurate diagnosis
- Treatment-resistant melanoma
- Brain metastases and leptomeningeal disease
- Rare melanomas
- Immunotherapy and cellular therapies
- Biomarkers and personalised treatment
- Patient access to clinical trials
Rare melanoma research includes acral, mucosal, uveal and paediatric melanoma.
Governance and Structure
MRA is governed by a Board of Directors chaired by co-founder Debra Black. Its operations are led by Chief Executive Officer Stephanie Kauffman.
Scientific funding decisions are supported by expert bodies that include:
- Scientific Advisory Panel
- Grant Review Committee
- Medical Advisory Panel
- Dermatology Council
These experts assess scientific quality, innovation, feasibility and the potential of proposed research to improve patient outcomes.
Funding and Grants
MRA raises funding through individual donations, corporate partnerships, sponsored research grants, fundraising events, workplace giving and planned gifts.
Its principal grant mechanisms include:
- Young Investigator Awards
- Established Investigator Awards
- Pilot Awards
- Academic–Industry Partnership Awards
- Collaborative and team-science funding
- Special research initiatives
- Next Steps funding
MRA supports individual researchers and collaborative teams working on innovative and translational melanoma research. Proposals are evaluated through a competitive peer-review process.
For the 2026–2027 cycle, MRA plans to provide at least $7.9 million in new funding through its general request for proposals.
Major Programs and Initiatives
- Research Grant Programme: Supports promising melanoma research at universities, hospitals and medical institutions worldwide.
- RARE Registry: Collects patient-reported information to strengthen research on rare melanomas.
- Scientific Retreat: Brings together more than 300 researchers, clinicians, patients and industry representatives to share emerging findings.
- Melanoma Exchange: Provides patients and caregivers with research, treatment and support information.
- Clinical Trial Navigator: Helps patients identify potentially relevant melanoma clinical trials.
- Patient Forum: Connects patients, caregivers, advocates, clinicians and researchers.
- Corporate Partnerships: Mobilises private-sector resources and public awareness for melanoma research.
Impact and Examples of Work Funded
Since 2007, MRA has:
- Invested more than $200 million in melanoma research
- Supported more than 500 research awards
- Leveraged approximately $500 million in additional collaborative and follow-on funding
- Funded research at institutions across numerous countries
- Contributed to progress in immunotherapy, targeted treatments and precision medicine
- Supported early-career scientists entering melanoma research
- Advanced research on rare and treatment-resistant melanomas
- Improved access to clinical-trial information
In 2026, MRA announced its largest annual global research investment—$18.4 million—to support melanoma detection, treatment and scientific innovation.
MRA-funded researchers have contributed to major advances in melanoma care, including research connected to more than 17 therapeutic approaches approved for patients.
Conclusion
The Melanoma Research Alliance is a leading global funder of scientific research addressing melanoma prevention, diagnosis and treatment. Its funding model combines expert peer review, international collaboration, patient engagement and support for both established and early-career researchers.
Researchers should review each funding announcement carefully because award amounts, eligibility rules and application deadlines vary by grant mechanism.
For more information, visit here.
